Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Our Businesses
Explore more Johnson & Johnson sites:
Switzerland
Page logo
Our Company

Johnson & Johnson Announces Dividend Increase of 5.0%
Johnson & Johnson Announces Dividend Increase of 5.0%

New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson today announced that its Board of Directors has declared a 5.0% increase in the quarterly dividend, from $1.01 per share to $1.06 per share.

“Despite a year of unprecedented disruption, Johnson & Johnson remained committed to its established financial principles that strengthen our ability to drive long-term value for stakeholders. In recognition of our notable 2020 results, strong financial position and confidence in the future of Johnson & Johnson, the Board of Directors has voted to increase the quarterly dividend for the 59th consecutive year,” said Alex Gorsky, Chairman and Chief Executive Officer of the company.

At the new rate, the indicated dividend on an annual basis is $4.24 per share compared to the previous rate of $4.04 per share. The next quarterly dividend is payable on June 8, 2021 to shareholders of record as of the close of business on May 25, 2021. The ex-dividend date is May 24, 2021.

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

# # #

  • Press Contacts:
    Christina Chan
    (732) 524-6297

    Courtney Dugan
    cdugan1@its.jnj.com
    (347) 452-1061

    Investor Contacts:
    Christopher DelOrefice
    (732) 524-2955

    Jennifer McIntyre
    (732) 524-3922
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue